Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393248 · ClinicalTrials.gov registry record · Phase 1
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 201
- Enrollment target
NCT02393248: Clinical Trial Phase 1 study, sponsored by Incyte Corporation.
NCT02393248 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 201 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (235% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02393248, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
Primary Outcome
Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2015-02-27 |
| Est. Completion | 2021-12-17 |
| Phase | Phase 1 |
Why NCT02393248 stopped before completion
NCT02393248 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (235% higher).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02393248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02393248 about?
NCT02393248 is a clinical study titled "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)". The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
What is the current status of trial NCT02393248?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 201 participants. The study started on 2015-02-27. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT02393248?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT02393248?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02393248's enrollment target sits among peer trials
201 258th of 2000 higher than 1,742 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI